These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28514405)

  • 1. [Stable high interleukin-17A concentration in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitors during a year].
    Gaydukova IZ; Rebrov AP; Aparkina AV; Khondkaryan EV
    Ter Arkh; 2017; 89(4):80-85. PubMed ID: 28514405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.
    Wendling D; Cedoz JP; Racadot E
    Joint Bone Spine; 2008 Oct; 75(5):559-62. PubMed ID: 18674944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ; Sørensen IJ; Garnero P; Johansen JS; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Lambert R; Hansen A; Østergaard M
    Ann Rheum Dis; 2011 Aug; 70(8):1375-81. PubMed ID: 21551511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
    Kilic E; Kilic G; Akgul O; Ozgocmen S
    Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Exploration of the mechanism of xinfeng capsule in the treatment of ankylosing spondylitis based on B and T lymphocyte attenuator and oxidative stress].
    Qi YJ; Liu J; Zheng L; Cao YX; Wan L
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jan; 35(1):25-32. PubMed ID: 25790670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
    Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
    Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender difference in ASAS HI among patients with ankylosing spondylitis.
    Chen HH; Chen YM; Lai KL; Hsieh TY; Hung WT; Lin CT; Tseng CW; Tang KT; Chou YY; Wu YD; Huang CY; Hsieh CW; Huang WN; Chen YH
    PLoS One; 2020; 15(7):e0235678. PubMed ID: 32645080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there any gender-specific difference in the cut-off values of ankylosing spondylitis disease activity score in patients with axial spondyloarthritis?
    Kilic G; Kilic E; Ozgocmen S
    Int J Rheum Dis; 2017 Sep; 20(9):1201-1211. PubMed ID: 27309497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of intravenous methylprednisolone in the treatment of patients with active ankylosing spondylitis: results of a 12-week, prospective, open-label, pilot (METALL) study].
    Gaydukova IZ; Rebrov AP; Poddubnyi DA
    Ter Arkh; 2015; 87(5):47-52. PubMed ID: 26155618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.
    Syngle A; Vohra K; Sharma A; Kaur L
    Clin Rheumatol; 2010 Jul; 29(7):763-70. PubMed ID: 20204669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
    Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
    BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.
    Machado P; Landewé RB; Braun J; Baraliakos X; Hermann KG; Hsu B; Baker D; van der Heijde D
    Ann Rheum Dis; 2012 Dec; 71(12):2002-5. PubMed ID: 22915615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VEGF and BMP-2 levels in patients with ankylosing spondylitis and the relationship to treatment with tumour necrosis factor alpha inhibitors.
    Tošovský M; Bradna P; Andrýs C; Andrýsová K; Cermáková E; Soukup T
    Acta Medica (Hradec Kralove); 2014; 57(2):56-61. PubMed ID: 25257151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.
    Rahman P; Choquette D; Bensen WG; Khraishi M; Chow A; Zummer M; Shaikh S; Sheriff M; Dixit S; Sholter D; Psaradellis E; Sampalis JS; Letourneau V; Lehman AJ; Nantel F; Rampakakis E; Otawa S; Shawi M
    BMJ Open; 2016 Apr; 6(4):e009661. PubMed ID: 27048632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Discriminative Values of the Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Spondyloarthritis-Related Axial Arthritis.
    Tsang HHL; Chung HY
    J Clin Rheumatol; 2017 Aug; 23(5):267-272. PubMed ID: 28661926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.